The Medudy course on biosimilars, presented by Professor Axel Merseburger, Director of the Department of Urology at the University of Lübeck, provides practical knowledge on the development, approval and use of biosimilars in everyday clinical practice.
Biosimilars are follow-on preparations of biologics which, due to their complex production in biological systems, are not identical copies, but only highly comparable products. Their development therefore requires complex analysis and clinical studies in order to prove efficacy and safety in comparison to the reference biologic. Professor Merseburger explains why biosimilars are considered as effective and safe as their reference products and how they also contribute to significant cost savings in the healthcare system.
Note: All "speakers" appearing in the Medudy videos are AI-based avatars, which are used to improve the didactics of the videos. The people on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy medical team.
The video was produced with the kind support of Sandoz Hexal.
At the end of this training you will know:
- the difference between generics and biosimilars
- the importance of comprehensive analytics for biosimilar development
- the concept of microheterogeneity
- the approval procedure for biosimilars
- the clinical and economic relevance of biosimilars for healthcare provision in the healthcare system
